

## **REMARKS**

### **Claim Amendment**

Claim 1 has been further amended by replacing “phenyl” with “aryl” in element R, which was in the original claim 1. In addition, in claim 1, the second NR9R10 in the element R<sup>1</sup> has been added back in and R9 and R10 for the second NR9R10 have been separately defined to break the infinite regression, support of which can be found in the original claim 5. Claim 5 is also amended to improve readability. New claims 14-17 have been added and they are supported by the original claims 10-13.

### **35 U.S.C. §102**

Claims 1-2 were rejected by the Examiner under 35 U.S.C. §102(a,e) as being anticipated by U.S. Patent No. 6,921,753. Applicants respectfully submit that the additional amendment to claim 1 should also overcome this rejection and withdrawal of this rejection is respectfully requested.

### **35 U.S.C. §112**

Claims 1-3 and 10-13 were rejected by the Examiner under 35 U.S.C. §112, second paragraph, as being indefinite. Specifically, the second NR9R10 in the element R1 causes an infinite regress. Applicants amended claim 1 by defining the second NR9R10 based on the support from original claim 5 to remove the infinite regress. Withdrawal of the rejection is respectfully requested.

Applicants continue to rely on all the other arguments presented in the earlier amendment dated July 30, 2007 that are still applicable in view of the new claim amendments to overcome all other rejections and issues raised by the Examiner.

Having now responded to all the outstanding issues in the Office Action, Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100729-1P US.

Respectfully submitted,  
/Jianzhong SHEN, Reg.#48076/

---

Name: Jianzhong Shen  
Dated: August 3, 2007  
Reg. No.: 48,076  
Phone No.: 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca  
1800 Concord Pike  
Wilmington  
DE-19850-5437